Biologic agents are increasingly used in the treatment of psoriasis, and have played an active role in addressing moderate to severe, refractory and special types of psoriasis. Biologic agents that have been approved for marketing and used in the treatment of psoriasis in China include 7 agents of 3 major categories, namely tumor necrosis factor-α inhibitors, interleukin 12/23 inhibitors and interleukin 17A inhibitors. How to use biologic agents in a rational, effective and safe way has become an issue of great concern in clinical practice. To this end, experts in the field of diagnosis and treatment of psoriasis and related fields in China developed this guideline based on Chinese and international research data, clinical experience, as well as characteristics of Chinese patients with psoriasis after in-depth discussions. This guideline provides specific guidance for clinicians in terms of application principles and methods of major biologic agents, efficacy and safety profiles, patient screening and monitoring, common problems and solutions, as well as considerations for their application in special populations.